U.S., Jan. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07355335) titled 'Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML' on Jan. 05.
Brief Summary: The purpose of this study is to evaluate the safety and tolerability of mezigdomide in combination with ziftomenib in adolescent and adult participants with either KMT2A-rearranged (KMT2A-r) or NPM1-mutant relapsed or refractory acute myeloid leukemia (AML).
Study Start Date: July 09, 2026
Study Type: INTERVENTIONAL
Condition:
KMT2A-rearranged
NPM1-mutant Refractory or Relapsed AML
Intervention:
DRUG: Ziftomenib
Capsule taken orally once daily on days 1-28 of each 28-day cycle.
DRUG: Mezigdomide
Capsule taken orally once daily on days 1-2...